Medication info
Crechek Tablet 10 mg (Rosuvastatin Calcium)

Crechek Tablet 10 mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Hanlim Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
28 tablets (14 tablets/PTP x 2), 30 tablets/bottle
Approval status
Active

MFDS item code 201310979 · Approved 2013.12.31 · Insurance code 645304780

Summary

Main use
Improvement of dyslipidemia; inhibition of atherosclerosis progression; prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia: Before and during treatment with this medicine, patients should follow a standard cholesterol-lowering diet and continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Assessment of renal function should be considered in these patients. There is no experience with use in patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Child dose
2. Pediatric patients with heterozygous familial hypercholesterolemia (10 to 17 years of age) The usual dose range is 5 milligrams to 20 milligrams once daily (there are no clinical data on doses higher than 20 milligrams in pediatric patients). The dose should be adjusted individually according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or longer. The safety and efficacy in children under 10 years of age have not been established.

Ingredients

Manufacturer
Hanlim Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia; inhibition of atherosclerosis progression; prevention of cardiovascular disease

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • dyslipidemia
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of premature coronary artery disease
View approved original text

This drug is used in patients with primary hypercholesterolemia and mixed dyslipidemia when dietary control and exercise do not suffice. It is also used as an adjunct to dietary changes and other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia. In patients with hypercholesterolemia, it lowers total cholesterol and LDL-cholesterol levels, delaying the progression of atherosclerosis. For pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia, it is used as a dietary adjunct to control cholesterol levels under strict guidelines. Additionally, it is effective as a dietary adjunct for patients with primary dysbetalipoproteinemia. It also helps reduce the risk of stroke, myocardial infarction, and vascular re-intervention in men over 50 years and women over 60 years with risk factors for cardiovascular disease. In summary, this medication is used for various dyslipidemias including hypercholesterolemia and familial hypercholesterolemia and for reducing cardiovascular disease risk.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia: Before and during treatment with this medicine, patients should follow a standard cholesterol-lowering diet and continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Assessment of renal function should be considered in these patients. There is no experience with use in patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Child dose

2. Pediatric patients with heterozygous familial hypercholesterolemia (10 to 17 years of age) The usual dose range is 5 milligrams to 20 milligrams once daily (there are no clinical data on doses higher than 20 milligrams in pediatric patients). The dose should be adjusted individually according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or longer. The safety and efficacy in children under 10 years of age have not been established.

Precautions

This drug should not be administered to certain patients. For example, it should not be used in patients with an allergy to the components of this drug, severely impaired liver function, muscle disease, severely reduced kidney function, women who are pregnant or breastfeeding, and in cases where it is taken with certain medications. It is important to regularly check liver function and muscle condition while using this drug. Patients who consume large amounts of alcohol, have a history of liver disease, hypothyroidism, decreased kidney function, and elderly patients should be especially cautious. If symptoms such as muscle pain, weakness, or cramps occur, notify healthcare personnel immediately, and it may be necessary to discontinue the medication. It is advisable to avoid conducting muscle-related tests immediately after intense exercise. This drug can affect liver function; therefore, treatment should be stopped immediately if jaundice or symptoms of liver damage appear. Blood sugar levels should also be monitored regularly, as the risk of diabetes may increase. The effectiveness and side effects of this drug may vary according to certain genetic factors, necessitating dosage adjustments based on the patient's condition. Severe skin reactions can occur rarely, so if severe rashes, redness, or swelling occur on the skin, the medication should be stopped immediately and medical advice sought. Concomitant use with other drugs may lead to interactions, so it is essential to inform healthcare personnel about all medications being taken. Notably, using this drug with specific antivirals, immunosuppressants, antibiotics, and fibrate medications may increase the risk of muscle-related side effects. Women who are pregnant or potentially pregnant must use adequate contraceptive methods, and should discontinue use immediately if pregnancy occurs. Use while breastfeeding is also not recommended. In cases of overdose, there are no specific antidotes, so treatment should be symptomatic while managing liver and muscle examinations. Dizziness may occur while taking this drug, so caution is advised when driving or operating machinery.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, multifocal neuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, elevated transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), drug-induced exanthema, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, fatigue, numbness, paresthesia, chest discomfort, anorexia, abdominal distension, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. Additionally, it is best to store the drug at room temperature between 1°C and 30°C, away from extreme heat or cold.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

28 tablets (14 tablets/PTP x 2), 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.